Harnessing Neurotrophin-3 Biology to Address the Underlying Drivers of Chronic Pain
2:00 pm - Wednesday 27th January 2027
- Exploring how excess neurotrophin-3 (NT-3) signalling contributes to chronic pain sensitisation and functional impairment across osteoarthritis and other painful conditions
- Reviewing Phase II clinical data for LEVI-04, a first-in-class p75NTR-Fc fusion protein, demonstrating significant improvements in pain, function and stiffness in patients with osteoarthritis
- Evaluating a differentiated approach to neurotrophin modulation that seeks to deliver meaningful analgesia while avoiding the joint safety concerns historically associated with anti-NGF therapies
- Assessing the future potential of NT-3 inhibition across osteoarthritis, musculoskeletal disorders and broader chronic pain indications
